Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: While there have been significant advances in our understanding of the autoimmune responses and the molecular nature of the target autoantigens in primary biliary cirrhosis (PBC), unfortunately these data have yet to be translated into new therapeutic agents. We have taken advantage of a unique murine model of autoimmune cholangitis in which mice expressing a dominant negative form of transforming growth factor β receptor II (dnTGFβRII), under the control of the CD4 promoter, develop an intense autoimmune cholangitis associated with serological features similar to human PBC. CD40-CD40 ligand (CD40L) is a major receptor–ligand pair that provides key signals between cells of the adaptive immune system, prompting us to determine the therapeutic potential of treating autoimmune cholangitis with anti-CD40L antibody (anti-CD40L; MR-1). Four-week-old dnTGFβRII mice were injected intraperitoneally with either anti-CD40L or control immunoglobulin (Ig)G at days 0, 2, 4 and 7 and then weekly until 12 or 24 weeks of age and monitored for the progress of serological and histological features of PBC, including rigorous definition of liver cellular infiltrates and cytokine production. Administration of anti-CD40L reduced liver inflammation significantly to 12 weeks of age. In addition, anti-CD40L initially lowered the levels of anti-mitochondrial autoantibodies (AMA), but these reductions were not sustained. These data indicate that anti-CD40L delays autoimmune cholangitis, but the effect wanes over time. Further dissection of the mechanisms involved, and defining the events that lead to the reduction in therapeutic effectiveness will be critical to determining whether such efforts can be applied to PBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J. (2010) · mAbs · doi:10.4161/mabs.2.3.11782 · Cited by 250
Kita, H., Matsumura, S., He, X.-S., Ansari, A. A., Lian, Z.-X., Van de Water, J., Coppel, R. L., Kaplan, M. M., & Gershwin, M. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214698 · Cited by 222
Self-citationRole of CD40 ligand in amyloidosis in transgenic Alzheimer's mice
Tan, J., Town, T., Crawford, F., Mori, T., DelleDonne, A., Crescentini, R., Obregon, D., Flavell, R. A., & Mullan, M. J. (2002) · Nature Neuroscience · doi:10.1038/nn968 · Cited by 217
Primary biliary cirrhosis and Sjögren’s syndrome: Autoimmune epithelitis
Selmi, C., Meroni, P. L., & Gershwin, M. E. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.11.005 · Cited by 145
Self-citationLleo, A., Liao, J., Invernizzi, P., Zhao, M., Bernuzzi, F., Ma, L., Lanzi, G., Ansari, A. A., Coppel, R. L., Zhang, P., et al. (2012) · Hepatology · doi:10.1002/hep.24630 · Cited by 133
Self-citationThe immunopathology of liver granulomas in primary biliary cirrhosis
You, Z., Wang, Q., Bian, Z., Liu, Y., Han, X., Peng, Y., Shen, L., Chen, X., Qiu, D., Selmi, C., et al. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.05.022 · Cited by 57
Self-citation
Cited by
The ascending pathophysiology of cholestatic liver disease
Jansen, P. L. M., Ghallab, A., Vartak, N., Reif, R., Schaap, F. G., Hampe, J., & Hengstler, J. G. (2017) · Hepatology · doi:10.1002/hep.28965 · Cited by 301
“Reduction of immune activity Anti-VAP1 Integrin blocker Anti CD 40 B cell depletion Targets T cells BTT1023 (91) Vedolizumab FFP104 (92) Rituximab Abatacept (93) PSC, 02239211 Approved for IBD PBC, 02193360 PBC, 02376335 PBC, 02078882, approved for”
BackgroundThe autoimmune basis of alopecia areata: A comprehensive review
Islam, N., Leung, P. S. C., Huntley, A. C., & Eric Gershwin, M. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.10.014 · Cited by 269
Self-citationExtrahepatic autoimmune conditions associated with primary biliary cirrhosis
Floreani, A., Franceschet, I., Cazzagon, N., Spinazzè, A., Buja, A., Furlan, P., Baldo, V., & Gershwin, M. E. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8427-x · Cited by 188
Self-citationThe bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Self-citation
Metadata
- Authors
- Tanaka, H., Yang, G.-X., Iwakoshi, N., Knechtle, S. J., Kawata, K., Tsuneyama, K., Leung, P., Coppel, R. L., Ansari, A. A., Joh, T., Bowlus, C., & Gershwin, M. E.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-24
- Volume
- 174
- Issue
- 3
- Pages
- 364-371
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W1692631379
- Cited by
- 45
- References
- 7
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.